Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.90 |
| ▸ | RAB9A | P51151 | 7/20 | 0.73 |
| ▸ | NPC1 | O15118 | 6/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | ATM | Q13315 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.69 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2835923 | 0.95 | PTPN1 (0.81) | PTPN1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6263820 | 0.93 | NPC1 (0.83) | PTPN1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8660366 | 0.93 | NPC1 (0.83) | PTPN1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2835618 | 0.92 | PTPN1 (0.94) | PTPN1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL29611669 | 0.92 | PTPN1 (0.94) | PTPN1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22223650 | 0.92 | PTPN1 (0.94) | PTPN1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2834528 | 0.89 | PTPN1 (0.73) | PTPN1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL18103163 | 0.87 | NPC1 (0.88) | PTPN1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL14715824 | 0.87 | NPC1 (0.88) | PTPN1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL4609805 | 0.86 | NPC1 (0.79) | PTPN1RAB9ANPC1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3049388-B1 | NUCLEATING AGENT FOR THERMOPLASTIC POLYMER COMPOSITION | MILLIKEN & CO (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2850068-B1 | N-(phenyl)-2-[[3-(phenyl)-1H-1,2,4-triazol-5-yl]thio]-acetamide derivatives and related compounds as G protein coupled receptor 17 (GPCR17) modulators for use in the treatment of neuro-degenerative diseases | UNIV DEGLI STUDI MILANO (IT) | 2019-05-29 | — | — | EP | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-9879030-B2 | GPR17 receptor modulators | UNIVERSITA′ DEGLI STUDI DI MILANO (IT) | 2018-01-30 | — | — | US | disclosed |
| US-9879030-B2 | GPR17 receptor modulators | UNIVERSITA′ DEGLI STUDI DI MILANO (IT) | 2018-01-30 | — | — | US | disclosed |
| US-9856252-B2 | 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2018-01-02 | — | — | US | disclosed |
| US-9856252-B2 | 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2018-01-02 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-20160222005-A1 | 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2016-08-04 | — | — | US | disclosed |
| EP-1660437-B1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2008-10-15 | — | — | EP | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007138033-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138033-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| US-7282522-B2 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2007-10-16 | — | — | US | disclosed |
| US-20060252834-A1 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2006-11-09 | — | — | US | disclosed |
| EP-1660437-A4 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2006-09-20 | — | — | EP | disclosed |
| EP-1660437-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | Amorepacific Corporation (KR) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019162-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORPORATION (KR) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | PTPN1 3023/4885RAB9A 1091/4885NPC1 52/4885 |
| US-20160222005-A1 | 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE | B2M, HBG2, BCAT2 | PTPN1 3551/4885RAB9A 3598/4885NPC1 3511/4885 |
| US-20060252834-A1 | Hydroxamic acid derivatives and the method for preparing thereof | HDAC7, SIRT7, HCAR1 | PTPN1 4406/4885RAB9A 4487/4885NPC1 2347/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PTPN1 3967/4885RAB9A 903/4885NPC1 608/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | PTPN1 3817/4885RAB9A 701/4885NPC1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.